Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

← catalyst calendar

NCT02952508

Sponsored by Cellectar Biosciences, Inc. (industry) · CLRB — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

120estimated

Sites

Countries

Australia, Brazil, Czechia +8

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2017-07-26

actual

When the study began enrolling

Primary completion

2026-06-22

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-12-22

estimated

The whole study's end, after follow-up

First posted

2016-11-02

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-03-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Waldenstrom Macroglobulinemia
Multiple Myeloma
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Lymphoplasmacytic Lymphoma
Marginal Zone Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma
Central Nervous System Lymphoma

Interventions

Drug: Iopofosine I 131 single dose — also filed as I-131-CLR1404, CLR 131
Drug: Iopofosine I 131 multiple dose — also filed as I-131-CLR1404, CLR 131
Drug: Iopofosine I 131 fractionated dose — also filed as I-131-CLR1404, CLR 131

Primary outcomes

what the primary-completion date above is the date OF

Part A [CLOVER-1] Clinical benefit rate

measured 84 days

Part B [CLOVER-WaM] Major Response Rate

measured 12 months

Permalink · CLRB's whole pipeline · Catalyst calendar · Every registered study · What changed